Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling the Peaks
(Stocks hitting 52-week highs on July 9)
- Aerpio Pharmaceuticals Inc (NASDAQ: ARPO)
- Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR)
- OptiNose Inc (NASDAQ: OPTN)
- Regenxbio Inc (NASDAQ: RGNX)
- Veracyte Inc (NASDAQ: VCYT)
- Vital Therapies Inc (NASDAQ: VTL)
Down In The Dumps
(Stocks hitting 52-week lows on July 9)
- Achaogen Inc (NASDAQ: AKAO)
- Auris Medical Holding AG (NASDAQ: EARS)
- ContraVir Pharmaceuticals Inc (NASDAQ: CTRV)
- CytRx Corporation (NASDAQ: CYTR)
- Opiant Pharmaceuticals Inc (NASDAQ: OPNT)
- Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP)
Stocks In Focus Acceleron-Celgene Combo's Blood Disorder Drug Aces Mid-stage Trial
Acceleron Pharma Inc (NASDAQ: XLRN) and Celgene Corporation (NASDAQ: CELG) announced their luspatercept, which is being evaluated in a Phase 2 study called BELIEVE in adults with transfusion-dependent beta-thalassemia achieved primary and all secondary endpoints.
The pipeline candidate achieved a highly statistically significant improvement in the primary endpoint of eythroid response, defined as at least a 33 percent reduction from baseline in RBC transfusion burden, with a reduction of at least 2 units for 12 consecutive weeks, from week 13 to week 24 compared to placebo.
The companies said they plan to submit regulatory filings in H1'19.
Acceleron shares rallied 12.87 percent to $53.50 in after-hours trading.
OncoCyte's Lung Cancer Diagnostic Blood Test Found Effective
OncoCyte Corp (NYSE: OCX) said its lung cancer diagnostic blood test named DetermaVu produced encouraging results in a most recent study of clinical samples, with performance better than previously anticipated. The company said the study supports moving the testing to a leading diagnostic testing platform.
Oncocyte shares soared 50.82 percent to $4.60.
Inspire's Device to Get Aetna Coverage
"Aetna's plan provides coverage for approximately 22 million members," Inspire said.
The Inspire therapy, according to the company, is a closed-loop, minimally invasive solution that provides comfort and convenience, resulting in high compliance for patients with moderate to severe obstructive sleep apnea.
The stock jumped 7.36 percent to $39.80 in after-hours trading.
Aquinox to Trim Workforce By 53 Percent
Aquinox Pharmaceuticals Inc (NASDAQ: AQXP) said in a filing that the Compensation Committee of its board approved a restructuring plan to reduce costs following its failed rosiptor trail announced in late June. The restructuring action includes reduction of its workforce by 30 employees or 53 percent.
The stock slumped 9.31 percent to $2.63 in after-hours trading.
On The Radar
Zogenix, Inc. (NASDAQ: ZGNX) is due to announce the results of the Phase 3 study of its ZX008, assessed in a study called Study 1504 for Dravet syndrome in early July.
FDA Commissioner Scott Gottlieb released a statement, wherein he said the agency is focused on striking a balance between reducing the rate of new addiction by reducing exposure to opioids, while at the same time enabling appropriate access to those patients who have legitimate medical need for these medicines.
See more from Benzinga
- Benzinga's Daily Biotech Pulse: Biogen And Eisai's Alzheimer's Drug Meets End Points In Mid-Stage Trial, Obseva To List Shares On Swiss Exchange
- A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.